Holding(s) in Company

RNS Number : 4121C
Circassia Pharmaceuticals Plc
16 January 2015
 



 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

Circassia Pharmaceuticals PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights


An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights

X

Other (please specify):



3. Full name of person(s) subject to the
notification obligation:
iii

OppenheimerFunds, Inc.

4. Full name of shareholder(s)
 (if different from 3.):iv


5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

13 January 2015

6. Date on which issuer notified:

14 January 2015

7. Threshold(s) that is/are crossed or
reached:
vi, vii

10% (increased to 11.00%)

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00BJVD3B28

10,805,820

10,805,820

20,839,269


20,839,269


11.00%



B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights







C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 





 

 

Nominal

Delta




Total (A+B+C)

Number of voting rights

Percentage of voting rights

20,839,269

11.00%



 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

 

OppenheimerFunds, Inc. ("OFI") is a registered investment advisor with the U.S. SEC.  Its ultimate parent company, Massachusetts Mutual Life Insurance Company, qualifies for disaggregation under FCA regulations.  The shares of the issuer are held by investment accounts managed by OFI.


Proxy Voting:

10. Name of the proxy holder:


11. Number of voting rights proxy holder will cease
to hold:


12. Date on which proxy holder will cease to hold
voting rights:




13. Additional information:



14. Contact name:

Julien Cotta (Chief Financial Officer)

15. Contact telephone number:

+ 44 (0) 1 865 405560

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUNASRVAAAAAR

Companies

Niox Group (NIOX)
UK 100

Latest directors dealings